Spotlight: NRx Pharmaceuticals Notes Presentation Of IV Ketamine Efficacy Versus Nasal Esketamine Efficacy At American Society Of Clinical Psychopharmacology (2026)
"The authors concluded that in routine clinical care, both IV ketamine and intranasal esketamine rapidly improve depression symptoms with IV ketamine showing higher remission and response rates than intranasal esketamine."
Why is this important? NRx is creating a preservative-free version of IV ketamine, that, if approved by the FDA for mental health and pain indications, will allow ketamine therapy to be covered by insurance plans, thereby increasing access to this cutting-edge treatment.
Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression
“Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis.”
Michael DeMarco, PhD